Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study

Patrick A. Ott; Yung Jue Bang; Dominique Berton-Rigaud; Elena Elez; Michael J. Pishvaian; Hope S. Rugo; Igor Puzanov; Janice M. Mehnert; Kyaw L. Aung; Juanita Lopez; Marion Carrigan; Sanatan Saraf; Mei Chen; Jean Charles Soria

doi:10.1097/01.ogx.0000527579.58363.20

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study

Patrick A. Ott, Yung Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J. Pishvaian, Hope S. Rugo, Igor Puzanov, Janice M. Mehnert, Kyaw L. Aung, Juanita Lopez, Marion Carrigan, Sanatan Saraf, Mei Chen, Jean Charles Soria

GI Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	26-27
Number of pages	2
Journal	Obstetrical and Gynecological Survey
Volume	73
Issue number	1
DOIs	https://doi.org/10.1097/01.ogx.0000527579.58363.20
State	Published - Jan 1 2018

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1097/01.ogx.0000527579.58363.20

Cite this

Ott, P. A., Bang, Y. J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J. M., Aung, K. L., Lopez, J., Carrigan, M., Saraf, S., Chen, M., & Soria, J. C. (2018). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study. Obstetrical and Gynecological Survey, 73(1), 26-27. https://doi.org/10.1097/01.ogx.0000527579.58363.20

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study. / Ott, Patrick A.; Bang, Yung Jue; Berton-Rigaud, Dominique et al.
In: Obstetrical and Gynecological Survey, Vol. 73, No. 1, 01.01.2018, p. 26-27.

Research output: Contribution to journal › Comment/debate › peer-review

Ott, PA, Bang, YJ, Berton-Rigaud, D, Elez, E, Pishvaian, MJ, Rugo, HS, Puzanov, I, Mehnert, JM, Aung, KL, Lopez, J, Carrigan, M, Saraf, S, Chen, M & Soria, JC 2018, 'Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study', Obstetrical and Gynecological Survey, vol. 73, no. 1, pp. 26-27. https://doi.org/10.1097/01.ogx.0000527579.58363.20

@article{87d1751fb6434c8ab696062f71bfac45,

title = "Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study",

author = "Ott, {Patrick A.} and Bang, {Yung Jue} and Dominique Berton-Rigaud and Elena Elez and Pishvaian, {Michael J.} and Rugo, {Hope S.} and Igor Puzanov and Mehnert, {Janice M.} and Aung, {Kyaw L.} and Juanita Lopez and Marion Carrigan and Sanatan Saraf and Mei Chen and Soria, {Jean Charles}",

note = "Funding Information: Dana-Farber Cancer Institute, Boston, MA (P.A.O.); Seoul National University College of Medicine, Seoul, Republic of Korea (Y.-J.B.); Institut de Canc{\'e}rologie de l'Ouest Centre Ren{\'e} Gauducheau, Saint-Herblain, France (D.B.-R.); Vall d'Hebron Institute of Oncology, Barcelona, Spain (E.E.); Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (M.J.P.); University of California San Francisco, San Francisco, CA (H.S.R.); Roswell Park Cancer Institute, Buffalo, NY (I.P.); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (J.M.M.); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (K.L.A.); The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom (J.L.); Merck, Kenilworth, NJ (M. Carrigan, S.S., M. Chen); and Gustave Roussy and University Paris-Sud, Villejuif, France (J.-C.S.)",

year = "2018",

month = jan,

day = "1",

doi = "10.1097/01.ogx.0000527579.58363.20",

language = "English (US)",

volume = "73",

pages = "26--27",

journal = "Obstetrical and Gynecological Survey",

issn = "0029-7828",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer

T2 - Results from the KEYNOTE-028 Study

AU - Ott, Patrick A.

AU - Bang, Yung Jue

AU - Berton-Rigaud, Dominique

AU - Elez, Elena

AU - Pishvaian, Michael J.

AU - Rugo, Hope S.

AU - Puzanov, Igor

AU - Mehnert, Janice M.

AU - Aung, Kyaw L.

AU - Lopez, Juanita

AU - Carrigan, Marion

AU - Saraf, Sanatan

AU - Chen, Mei

AU - Soria, Jean Charles

N1 - Funding Information: Dana-Farber Cancer Institute, Boston, MA (P.A.O.); Seoul National University College of Medicine, Seoul, Republic of Korea (Y.-J.B.); Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain, France (D.B.-R.); Vall d'Hebron Institute of Oncology, Barcelona, Spain (E.E.); Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (M.J.P.); University of California San Francisco, San Francisco, CA (H.S.R.); Roswell Park Cancer Institute, Buffalo, NY (I.P.); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (J.M.M.); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (K.L.A.); The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom (J.L.); Merck, Kenilworth, NJ (M. Carrigan, S.S., M. Chen); and Gustave Roussy and University Paris-Sud, Villejuif, France (J.-C.S.)

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85041111851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041111851&partnerID=8YFLogxK

U2 - 10.1097/01.ogx.0000527579.58363.20

DO - 10.1097/01.ogx.0000527579.58363.20

M3 - Comment/debate

AN - SCOPUS:85041111851

SN - 0029-7828

VL - 73

SP - 26

EP - 27

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

IS - 1

ER -

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this